Not stock advice. Agent-generated research that may contain errors or omissions — informational only, not a recommendation to buy or sell any security. Do your own research and invest wisely. Quotes via Yahoo Finance (unaffiliated).
% = share price change, close 23 Sep → 3 Nov 2026
U.S. commercial revenue surged 148% YoY to $984M, surpassing government revenue.
RISKQ4 growth decelerates to 15% sequential from Q3's 20%.
Backlog reached $340B with $164B in defense; adjusted EPS jumped 33% to $2.26.
RISKDetailed 2027 financial guidance deferred to January earnings call.
Backlog hit record $292B; Q3 sales rose 11% to $20.7B with EPS of $7.97.
RISKFree cash flow declined to $3.0B from $3.3B in prior-year Q3.
Q1 FY2027 awards totaled $4.8B with 2.0x book-to-bill; 61% was new business.
RISKFree cash flow declined 6.6% YoY to $133.5M; DSO increased to 59 days.
Q3 sales hit record $2.22B, up 17% YoY; adjusted EPS raised to $8.53–$8.57.
RISKIndicor acquisition contributed ~$100M of Q3 revenue; integration risks remain.
Five defense contractors and software firms disclosed record backlogs, contract awards, and raised guidance over the past month. Growth catalysts span 2027–2035, with near-term execution risks in cash flow and margin pressure.
-
U.S. commercial revenue surged 148% year-over-year to $984 million in Q3 2026, surpassing U.S. government revenue.
NEWS Palantir Q3 2026 earnings beat, guidance raised CNBC www.cnbc.com -
Record backlog reached $340 billion, including $164 billion in defense backlog.
RELEASE RTX reports Q3 2026 results Raytheon Technologies www.rtx.com -
Lockheed's backlog hit a record $292 billion; Q3 2026 sales rose 11% year-over-year to $20.7 billion.
NEWS Lockheed Martin Q3 2026 sales up 11%, EPS $7.97, backlog hits $292B TradingView www.tradingview.com -
Q1 FY2027 contract awards of $4.8 billion with a 2.0x book-to-bill ratio; 61% of awards were new business.
RELEASE CACI Reports Results for Its Fiscal 2027 First Quarter CACI investor.caci.com -
Q3 2026 sales reached record $2.22 billion, up 17% year-over-year.
RELEASE AMETEK announces record third quarter 2026 results and raises full-year guidance PR Newswire www.tradingview.com
Research publicly traded companies across every sector and find the five with the best growth opportunities, as evidenced by what they disclosed in the last 30 days: earnings releases and guidance, SEC filings, contract awards, backlog, capacity, and product or regulatory milestones. Weigh every sector against the others rather than taking a quota from each. Order the five by growth potential, highest first — the largest and best-evidenced growth the disclosures support at the top — not by recent price momentum. Look across the next three to six months, and say so: rank on growth catalysts the company itself disclosed or guided to inside that window, never on a forecast of your own. This is growth-potential research: for each name give the growth timeline the company itself disclosed or guided to, and one disclosed fact that cuts against the thesis. Report observations only — no entry or exit points, no price targets, no advice on when to buy or sell.
- Search earnings releases, filings, and guidance across every sector from the last 30 days
- Rank five names by growth potential, highest and best-evidenced first — not price momentum
- For each, record the growth timeline the company itself disclosed
- For each, record one disclosed fact that cuts against the thesis
- Re-open every cited document and confirm it says what the note claims
- Drop any source that cannot be opened or does not support its sentence
- Emit ranked-list JSON within the schema caps
Adds this workflow to your account. Nothing is scheduled until you say so.